Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
Open Access
- 28 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 90 (8), 959-970
- https://doi.org/10.1007/s00109-012-0863-6
Abstract
Among oncolytic viruses, the vesicular stomatitis virus (VSV) is especially potent and a highly promising agent for the treatment of cancer. But, even though effective against multiple tumor entities in preclinical animal models, replication-competent VSV exhibits inherent neurovirulence, which has so far hindered clinical development. To overcome this limitation, replication-defective VSV vectors for cancer gene therapy have been tested and proven to be safe. However, gene delivery was inefficient and only minor antitumor efficacy was observed. Here, we present semireplication-competent vector systems for VSV (srVSV), composed of two trans-complementing, propagation-deficient VSV vectors. The de novo generated deletion mutants of the two VSV polymerase proteins P (phosphoprotein) and L (large catalytic subunit), VSVΔP and VSVΔL respectively, were used mutually or in combination with VSVΔG vectors. These srVSV systems copropagated in vitro and in vivo without recombinatory reversion to replication-competent virus. The srVSV systems were highly lytic for human glioblastoma cell lines, spheroids, and subcutaneous xenografts. Especially the combination of VSVΔG/VSVΔL vectors was as potent as wild-type VSV (VSV-WT) in vitro and induced long-term tumor regression in vivo without any associated adverse effects. In contrast, 90% of VSV-WT-treated animals succumbed to neurological disease shortly after tumor clearance. Most importantly, even when injected into the brain, VSVΔG/VSVΔL did not show any neurotoxicity. In conclusion, srVSV is a promising platform for virotherapeutic approaches and also for VSV-based vector vaccines, combining improved safety with an increased coding capacity for therapeutic transgenes, potentially allowing for multipronged approaches.Keywords
This publication has 25 references indexed in Scilit:
- Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes NeurotropismJournal of Virology, 2011
- Induction of Interferon and Interferon Signaling Pathways by Replication of Defective Interfering Particle RNA in Cells Constitutively Expressing Vesicular Stomatitis Virus Replication ProteinsJournal of Virology, 2010
- Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsGynecologic Oncology, 2010
- Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA TargetingJournal of Virology, 2010
- Some Attenuated Variants of Vesicular Stomatitis Virus Show Enhanced Oncolytic Activity against Human Glioblastoma Cells relative to Normal Brain CellsJournal of Virology, 2010
- Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionProceedings of the National Academy of Sciences of the United States of America, 2010
- A trans -Complementing Recombination Trap Demonstrates a Low Propensity of Flaviviruses for Intermolecular RecombinationJournal of Virology, 2010
- Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesVirology, 2007
- Synergistic Attenuation of Vesicular Stomatitis Virus by Combination of Specific G Gene Truncations and N Gene TranslocationsJournal of Virology, 2007
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1931